Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-05-01, Stock:NVS, The news for the past five days is as follows:
2018-04-24: NEWS1: Top Research Reports for Johnson & Johnson, Honeywell & Morgan Stanley.NEWS2: Top Research Reports for Johnson & Johnson, Honeywell & Morgan Stanley.NEWS3: Top Research Reports for Johnson & Johnson, Honeywell & Morgan Stanley.NEWS4: Centene (CNC) Q1 Earnings & Revenues Top, '18 View Lowered.NEWS5: Centene (CNC) Q1 Earnings & Revenues Top, '18 View Lowered.NEWS6: Notable ETF Inflow Detected - VXUS, NSRGY, TSM, NVS.NEWS7: Notable ETF Inflow Detected - VXUS, NSRGY, TSM, NVS.NEWS8: Is Bellicum Pharmaceuticals, Inc. a Buy?.NEWS9: Is Bellicum Pharmaceuticals, Inc. a Buy?.NEWS10: This Small Biotech Is Building on a Surprising Success.NEWS11: This Small Biotech Is Building on a Surprising Success.NEWS12: The Swiss Stock Market.NEWS13: The Swiss Stock Market.NEWS14: Is Biopharma Investing Too Much In Cancer R&D?.
2018-04-25: NEWS1: 5 Biotech ETFs for Outsized Gains.NEWS2: Analysts’ Views on Sanofi, Pre-1Q18 Earnings Release.NEWS3: Amgen (AMGN) Earnings Beat Estimates in Q1, Revenues Up Y/Y.NEWS4: Amgen (AMGN) Earnings Beat Estimates in Q1, Revenues Up Y/Y.NEWS5: Novartis Delivered Strong Performance in 1Q18.NEWS6: Anthem (ANTM) Beats on Q1 Earnings, Raises '18 Guidance.NEWS7: Anthem (ANTM) Beats on Q1 Earnings, Raises '18 Guidance.NEWS8: Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX.NEWS9: Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX.NEWS10: GlaxoSmithKline: Operating Revenues Up in 1Q18 Earnings.NEWS11: Novartis Launches FocalView to Modernize Clinical Trials.NEWS12: Amgen’s Earnings Grow 12% Year-Over-Year in 1Q18.NEWS13: The Zacks Analyst Blog Highlights: Johnson & Johnson, Honeywell, Morgan Stanley, Novartis and eBay.NEWS14: The Zacks Analyst Blog Highlights: Johnson & Johnson, Honeywell, Morgan Stanley, Novartis and eBay.NEWS15: Gilead Sciences has a Strong Oncology Research Program.NEWS16: The Swiss Stock Market Pulled Back With The Rest Of Europe.NEWS17: The Swiss Stock Market Pulled Back With The Rest Of Europe.NEWS18: The Zacks Analyst Blog Highlights: Johnson & Johnson, Honeywell, Morgan Stanley, Novartis and eBay.NEWS19: Glaxo (GSK) Misses on both Earnings and Revenue in Q1.NEWS20: Novartis' digital drive continues with eye-disease app.NEWS21: Novartis' digital drive continues with eye-disease app.NEWS22: [$$] How Long Till the Final World Malaria Day?.
2018-04-26: NEWS1: Universal Health (UHS) Q1 Earnings & Revenues Lag Estimates.NEWS2: Universal Health (UHS) Q1 Earnings & Revenues Lag Estimates.NEWS3: The Swiss Stock Market Finished With A Substantial Gain.NEWS4: The Swiss Stock Market Finished With A Substantial Gain.NEWS5: What Wall Street Analysts Estimate for Johnson & Johnson.
2018-04-27: NEWS1: Biotech Stocks Facing FDA Decision In May.NEWS2: Biotech Stocks Facing FDA Decision In May.NEWS3: How Vertex Pharmaceuticals’ Drugs Performed in 1Q18.NEWS4: GlaxoSmithKline’s 1Q18 Earnings: Revenue Trend.NEWS5: How Did BioMarin Pharmaceutical Perform in 1Q18?.NEWS6: Roche (RHHBY) Q1 Earnings: Ocrevus, Perjeta Drive Sales Beat.NEWS7: Roche (RHHBY) Q1 Earnings: Ocrevus, Perjeta Drive Sales Beat.NEWS8: What's in the Cards for Conatus (CNAT) This Earnings Season?.NEWS9: What's in the Cards for Conatus (CNAT) This Earnings Season?.NEWS10: Greek parliament cannot investigate Novartis case, committee says.NEWS11: Can Jafaki Help Incyte (INCY) Beat Earnings Estimates in Q1?.NEWS12: Can Jafaki Help Incyte (INCY) Beat Earnings Estimates in Q1?.NEWS13: The Swiss Stock Market Finished Little Changed In Choppy Trade.NEWS14: The Swiss Stock Market Finished Little Changed In Choppy Trade.
2018-04-30: NEWS1: FDA Oks Tafinlar + Mekinist For Adjuvant Treatment Of BRAF V600-mutant Melanoma.NEWS2: FDA Oks Tafinlar + Mekinist For Adjuvant Treatment Of BRAF V600-mutant Melanoma.NEWS3: Teva: ‘Hold’ Ratings from 55% of Analysts before 1Q18 Results.NEWS4: Analysts Raise Teva’s Earnings Estimates before Its 1Q18 Results.NEWS5: Could Teva Exceed Analysts’ Sales Estimates for 1Q18?.NEWS6: GlaxoSmithKline’s 1Q18 Earnings: Consumer Healthcare Business.NEWS7: The Swiss Stock Market Climbed On Roche Strength.NEWS8: The Swiss Stock Market Climbed On Roche Strength.

Answer: Decrease